BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17622579)

  • 1. Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action.
    Gardell SJ; Krueger JA; Antrilli TA; Elokdah H; Mayer S; Orcutt SJ; Crandall DL; Vlasuk GP
    Mol Pharmacol; 2007 Oct; 72(4):897-906. PubMed ID: 17622579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO; Verhamme I; Shore JD
    Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.
    Cale JM; Li SH; Warnock M; Su EJ; North PR; Sanders KL; Puscau MM; Emal CD; Lawrence DA
    J Biol Chem; 2010 Mar; 285(11):7892-902. PubMed ID: 20061381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SP-40,40 is a component of plasminogen activator inhibitor-1-binding protein and stabilizes plasminogen activator inhibitor-1 activity.
    Choi-Miura N
    Biol Pharm Bull; 2001 Jan; 24(1):39-42. PubMed ID: 11201243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.
    Crandall DL; Elokdah H; Di L; Hennan JK; Gorlatova NV; Lawrence DA
    J Thromb Haemost; 2004 Aug; 2(8):1422-8. PubMed ID: 15304050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk.
    Demers-Mathieu V; Underwood MA; Dallas DC
    Front Pediatr; 2022; 10():917179. PubMed ID: 36016873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.
    Pedersen KE; Einholm AP; Christensen A; Schack L; Wind T; Kenney JM; Andreasen PA
    Biochem J; 2003 Jun; 372(Pt 3):747-55. PubMed ID: 12656676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells.
    Song CY; Kim BC; Hong HK; Kim BK; Kim YS; Lee HS
    Am J Physiol Renal Physiol; 2002 Sep; 283(3):F423-30. PubMed ID: 12167592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1.
    Schatz F; Aigner S; Papp C; Toth-Pal E; Hausknecht V; Lockwood CJ
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2504-10. PubMed ID: 7629251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity.
    Boncela J; Papiewska I; Fijalkowska I; Walkowiak B; Cierniewski CS
    J Biol Chem; 2001 Sep; 276(38):35305-11. PubMed ID: 11418606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
    Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.